Details

Autor(en) / Beteiligte

• Shim, Seung-Hyuk
• Lee, Jung-Yun
• Lee, Yoo-Young
• Park, Jeong-Yeol
• Lee, Yong Jae
• Kim, Se Ik
• Han, Gwan Hee
• Yang, Eun Jung
• Noh, Joseph J
• Yim, Ga Won
• Son, Joo-Hyuk
• Kim, Nam Kyeong
• Kim, Tae-Hyun
• Kong, Tae-Wook
• Choi, Youn Jin
• Cho, Angela
• Lim, Hyunji
• Jang, Eun Bi
• Cho, Hyun Woong
• Suh, Dong Hoon

Titel

Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer

Ist Teil von

• Journal of Gynecologic Oncology, 2024, 35(2), , pp.1-19

Ort / Verlag

Korea (South): Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, Japan Society of Gynecologic Oncology

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.